Cocrystal Pharma, Inc.

Quick facts

Phase 2 pipeline

• CC-42344 · Infectious Disease
  CC-42344 is a small molecule inhibitor of the SARS-CoV-2 main protease.
• CDI-31244 · Infectious Diseases
  CDI-31244 is a small molecule inhibitor targeting the SARS-CoV-2 main protease.

Phase 1 pipeline

• CDI-988

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Cocrystal Pharma, Inc. portfolio CI brief
• Cocrystal Pharma, Inc. pipeline updates RSS